Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021.
Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021.
复制标题
DOI：
10.2807/1560-7917.es.2021.26.21.2100438
复制
发表时间：
2021-05
期刊：
影响因子：
--
通讯作者：
Working Group for the Study of COVID-19 in Navarra
中科院分区：
文献类型：
--
作者：
Martínez-Baz I;Miqueleiz A;Casado I;Navascués A;Trobajo-Sanmartín C;Burgui C;Guevara M;Ezpeleta C;Castilla J;Working Group for the Study of COVID-19 in Navarra
在2021年1月至4月期间确诊病例的密切接触者中评估了COVID-19疫苗的有效性。在20，961名接触者中，有7，240人被确认感染SARS-CoV-2，其中5，467人有症状，559人导致住院。非品牌特异性一剂次和二剂次疫苗有效率分别为35%（95%置信区间（CI）：25 - 44）和66%（95% CI：57 - 74）抗感染，42%（95% CI：31至52）和82%（95% CI：74至88），以及72%（95% CI：47至85）和95%（95% CI：62至99）。第二次剂量显著提高了有效性。研究结果支持继续全面接种疫苗。
COVID-19 vaccine effectiveness was evaluated in close contacts of cases diagnosed during January–April 2021. Among 20,961 contacts, 7,240 SARS-CoV-2 infections were confirmed, with 5,467 being symptomatic and 559 leading to hospitalisations. Non-brand-specific one and two dose vaccine effectiveness were respectively, 35% (95% confidence interval (CI): 25 to 44) and 66% (95% CI: 57 to 74) against infections, 42% (95% CI: 31 to 52) and 82% (95% CI: 74 to 88) against symptomatic infection, and 72% (95% CI: 47 to 85) and 95% (95% CI: 62 to 99) against COVID-19 hospitalisation. The second dose significantly increased effectiveness. Findings support continuing complete vaccination.